5 Results for "

Qi site

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Qi site" in MCE Product Catalog:

  • Targets Recommended:
Cat. No.: HY-13836
CAS No.: 1354745-52-0
Purity:  ≥98.0%
Target:  

Parasite

Research Areas:  

Infection

ELQ-300 is a potent and orally bioavailable antimalarial agent, acts as an inhibitor of the reductive (Qi) site of the cytochrome bc1 complex (cyt bc1). ELQ-300 inhibits growth of P. falciparum Dd2, Tm90-C2B, and D1 with IC50 values of 6.6, 4.6 and 160 nM, respectively. ELQ-300 can be used for the research of antimalarial .
loading...
    loading...
Cat. No.: HY-162066
CAS No.: 2868298-43-3
Target:  

Parasite

Research Areas:  

Infection

DNDI-6174 is an orally active Leishmania cytochrome b (Qi site of cytochrome bc1 complex/complex III) inhibitor. DNDI-6174 binds to the Qi site of Leishmania cytochrome b, inhibits cytochrome bc1 complex activity in the parasite's electron transport chain across promastigote and axenic amastigote stages. DNDI-6174 reduces parasite burden in rodent models, inhibits growth of various Leishmania species, drug-resistant clinical isolates, and Trypanosoma cruzi, with marginal activity against Trypanosoma brucei. DNDI-6174 can be used for the research of visceral leishmaniasis, cutaneous leishmaniasis .
loading...
    loading...
Cat. No.: HY-122298
CAS No.: 517875-34-2
Synonyms: XDE 777
Target:  

Antibiotic Fungal

Research Areas:  

Infection

Fenpicoxamid is a new fungicide. Fenpicoxamid inhibits the growth of the fungus Z. tritici with an EC50 value of 0.051 mg/L .
loading...
    loading...
Cat. No.: HY-184395
Target:  

Parasite

Research Areas:  

Infection

HLQ-102 is an orally active parasite cytochrome bc1 complex Qi site binder. HLQ-102 inhibits the growth of Plasmodium. HLQ-102 exhibits antimalarial activity against Plasmodium in mice. HLQ-102 can be used in malaria-related research .
loading...
    loading...
Cat. No.: HY-182711
CAS No.: 1379615-30-1
Target:  

Bacterial Parasite

Research Areas:  

Infection

SCR0911 is an inhibitor of mycobacterial cytochrome bcc oxidase and Plasmodium falciparum cytochrome bc1. SCR0911 disrupts oxidative phosphorylation by binding to mycobacterial cytochrome bcc, binds to the Qi site of Plasmodium falciparum cytochrome bc1, inhibits mycobacterial cell growth and ATP synthesis, and exhibits broad-spectrum anti-mycobacterial and anti-malarial activities. SCR0911 can be used in research related to tuberculosis, malaria, and isolated persistent hypermethioninemia (iph) .
loading...
    loading...